Avalo Therapeutics, Inc.
AVTX· Nasdaq
Released May 9, 2019, after the close
10-Q filed May 9, 2019, 39 days after period end · 0001628280-19-006439
| Metric | Q1 2019 | Q1 2018 | Q1 2017 | Q1 2016 |
|---|---|---|---|---|
| Revenue | $2.58M | $4.48M | $384.00 | — |
| Net Income | -$7.45M | -$3.88M | -$1.96M | -$5.14M |
| EPS Diluted |
Avalo Therapeutics, Inc. · CIK 1534120 · Engraved from SEC EDGAR
| — |
| -$0.12 |
| -$0.19 |
| -$0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.